PL EN


Preferences help
enabled [disable] Abstract
Number of results
2017 | 78 | 249-254
Article title

Innovation immunomodulatory treatment – case study of men diagnosed with relapsing-remitting multiple sclerosis (MS)

Content
Title variants
Languages of publication
EN
Abstracts
EN
Multiple Sclerosis (MS) is a complex disease that interferes with environmental factors and genetically predisposed conditions. This is a chronic, inflammatory disease of the central nervous system in which demyelination of neural tissue occurs. It is most often the case for young people with a slightly higher prevalence among women than men. Occurrence is rising in countries far from the equator, and the highest incidence is observed in temperate white people. This disease is characterized by so-called "rolls" that can last from 24 hours to several weeks. At this time there is a sudden increase in the existing symptoms or the appearance of a new one. The first signs of the disease are often mild and tend to cease quickly. The name reflects the spread of the pathological process in various places in the nervous system as well as the spread of changes over time. Regardless of the recognized form, the effect of MS is disability and reduced quality of life, which hinders self-reliance, self-care and freedom of movement. This paper is a case study of 49-year-old patient diagnosed with relapsing-remitting MS included in the experimental program of immunomodulatory treatment.
Year
Volume
78
Pages
249-254
Physical description
Contributors
  • Department of Animal and Human Physiology, University of Gdansk, Gdansk, Poland
  • Students’ Scientific Society Homunculus, University of Gdansk, Gdansk, Poland
  • Students’ Scientific Society Homunculus, University of Gdansk, Gdansk, Poland
References
  • [1] Rosati G., The prevalence of multiple sclerosis in the world: an update. Neurological Sciences 22, 2 (2001) 117-139
  • [2] Amankwah N., Marrie R. Multiple sclerosis in Canada 2011 to 2031: results of
  • a microsimulation modelling study of epidemiological and economic impacts. Health Promot Chronic Dis Prev Can 37, 2 (2017) 37-48
  • [3] Miller D., Barkhof F., Montalban X., Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet neurology 4, 5 (2005) 281-288
  • [4] Lassmann H. Experimental models of multiple sclerosis. Rev. Neurol. (Paris) 163, 6-7 (2007) 651-655
  • [5] The International Multiple Sclerosis Genetics Consortium. Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. N Engl J Med 357 (2007) 851-862
  • [6] Rentzos M., Nikolaou C. Serum uric acid and multiple sclerosis. Clinical neurology and neurosurgery 108, 6 (2006) 527-531
  • [7] Paty D. et al. MS COSTAR: a computerized patient record adapted for clinical research purposes. Annals of Neurology 36 (1994) 134-135
  • [8] de Seze J., Zephir H., Hautecoeur P., Mackowiak A., Cabaret M., Vermersch P. Pathologic laughing and intractable hiccups can occur early in multiple sclerosis. Neurology 67, 9 (2006) 1684-1686
  • [9] Confavreux C. Infections and the risk of relapse in multiple sclerosis. Brain 125, 5 (2002) 933–934.
  • [10] McDonald W., Compston A., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50, 1 (2000) 121-127
  • [11] Polman Ch., Reingold S., et al. Diagnostic criteria for Multiple Sclerosis: 2005 revisions to the „McDonald Criteria” Ann Neurol 58 (2005) 840-846
  • [12] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 11 (1983) 1444-1452
  • [13] Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-52.
  • [14] Traynor K. Dalfampridine approved for MS. Am J Health Syst Pharm 67, 5 (2010) 335
  • [15] Sriram S., Steiner I. Experimental Allergic Encephalomyelitis: A misleading model of Multiple Sclerosis. Annals of Neurology 58 (2005) 939-945
  • [16] Zipp F., Ellwardt E., Pramanik G., Mittmann T., Stroh A. Cortical Hyperactivity beyond the Immune Attack: Starting Point of Neurodegeneration. Neurology 86 (16 Supplement) (2016) 2.002
  • [17] Montalban X., Hause S., Kappos L., et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 (2017) 209-220
  • [18] Weinshenker, B. Natural history of multiple sclerosis. Annals of Neurology 36 (Suppl) (1994) 6-11
  • [19] Pittock S., McClelland R., Mayr W., Jorgensen N., Weinshenker B., Noseworthy J., Rodriguez M. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study Ann Neurol 2, 56 (2004) 303-306
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-b917a353-aec9-4408-96b1-6d206556ff1b
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.